Chronic Immune Thrombocytopenia (ITP) is an autoimmune disorder characterized by an abnormally low platelet count, which can lead to an increased risk of bleeding and bruising. In this condition, the immune system mistakenly attacks and destroys platelets, essential components of blood that help with clotting. Managing chronic ITP often requires a strategic approach to restore platelet levels and minimize bleeding risks while addressing the underlying immune dysfunction. Medications for chronic ITP are designed to either boost platelet production, suppress the overactive immune response, or directly manage bleeding symptoms. Treatments may include corticosteroids to reduce inflammation and immune activity, thrombopoietin receptor agonists to stimulate platelet production, and immunosuppressants to target the autoimmune process. In some cases, intravenous immunoglobulin (IVIG) or anti-D immunoglobulin may be used to temporarily raise platelet counts.
|
|
|
|
